Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06175780 is registered in ClinicalTrials.gov with Novatim Immune Therapeutics (Zhejiang) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors
- Lead sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- December 28, 2022
- Completion date
- December 28, 2025
- Enrollment
- 189 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.